Startup profile · funding coverage
AKASA
Generative AI platform automating healthcare revenue cycle operations.
Stage
series b
Status
private
Coverage
full
Why AKASA is interesting
Unified automation for medical coding, prior auth, and claims — deployed across 650+ hospitals in customer base per company site.
Key facts
- Series A (2019): led by a16z Bio + Health (a16z announcement)
- Series B (2021): $60M led by BOND with a16z and Costanoa participation (company press)
- Later rounds included Coatue per public reporting
Investors in our directory
Funds linked from AKASA's profile — open a fund page for stage focus and related deal articles.
Industries
Healthtech AI & Machine Learning
Industry hub pages are rolling out from our fund-derived baseline taxonomy.
Related funding articles
Venture Capital Tracker pieces that cover AKASA's financing or category context.
FAQs about AKASA
Funding context and why this company shows up in venture coverage.
AKASA automates revenue cycle operations (coding, prior auth, claims) with generative AI for hospitals — reducing administrative cost in the back office of care delivery.
a16z Bio + Health led the Series A (2019). Directory-linked investors include a16z (/fund/andreessen-horowitz) and Coatue (/fund/coatue).
Series B after a $60M round (2021) led by BOND with a16z participation; company reports deployment across 650+ hospitals.
Revenue cycle is labor-intensive and error-prone. AKASA targets full-workflow automation rather than point solutions for coding or denials alone.
No — AKASA remains private as of July 2026.
Last updated: 2026-07-24